Targeted therapies: a nursing perspective
- PMID: 16616280
- DOI: 10.1016/j.soncn.2006.01.009
Targeted therapies: a nursing perspective
Abstract
Objectives: To review the development of targeted therapies and the biology of relevant therapeutic targets. To analyze the relevance of targeted agents as part of current clinical practice.
Data sources: Research articles.
Conclusion: Several targeted agents are now available for clinical use. Their mechanisms of action are more specific against tumor cells than traditional cytotoxics. Monotherapy regimens based on targeted agents tend to be better tolerated than chemotherapy, and most combination regimens with targeted agents have proven feasible. Their availability has greatly expanded cancer treatment options, especially for chemorefractory patients.
Implications for nursing practice: Nurses involved in the care of patients with cancer can benefit from an increased understanding of targeted therapies, including their mechanisms of action, their efficacy profile, as well as prophylaxis and management of adverse events and administration procedures.
Similar articles
-
Targeted therapies: aiming for the bull's-eye.ONS Connect. 2007 Jul;22(7):8-12. ONS Connect. 2007. PMID: 17694778 No abstract available.
-
EGFR as a target: rationale for therapy.Semin Oncol Nurs. 2006 Feb;22(1 Suppl 1):5-9. doi: 10.1016/j.soncn.2006.01.010. Semin Oncol Nurs. 2006. PMID: 16616281 Review.
-
EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.Crit Rev Oncol Hematol. 2007 Apr;62(1):53-61. doi: 10.1016/j.critrevonc.2006.12.008. Epub 2007 Feb 26. Crit Rev Oncol Hematol. 2007. PMID: 17324578 Review.
-
Review: side effects of approved molecular targeted therapies in solid cancers.Oncologist. 2007 Dec;12(12):1443-55. doi: 10.1634/theoncologist.12-12-1443. Oncologist. 2007. PMID: 18165622 Review.
-
Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future.JOP. 2007 Jan 9;8(1):4-15. JOP. 2007. PMID: 17228128 Review.
Cited by
-
Synthesis and Characterization of an Epidermal Growth Factor Receptor-Selective RuII Polypyridyl-Nanobody Conjugate as a Photosensitizer for Photodynamic Therapy.Chembiochem. 2020 Feb 17;21(4):531-542. doi: 10.1002/cbic.201900419. Epub 2019 Oct 22. Chembiochem. 2020. PMID: 31339225 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources